




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C07D 263/38, A61K 31/42	A1	(11) International Publication Number: WO 97/34882 (43) International Publication Date: 25 September 1997 (25.09.97)
(21) International Application Number: PCT/EP97/01386		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 19 March 1997 (19.03.97)		
(30) Priority Data: P 9600685 21 March 1996 (21.03.96) ES		
(71) Applicant (for all designated States except US): GRUPO FARMACEUTICO ALMIRALL, S.A. [ES/ES]; 6 ^a Planta, Ronda del General Mitre, 151, E-0822 Barcelona (ES).		Published With international search report.
(72) Inventors; and		
(75) Inventors/Applicants (for US only): PUIG DURAN, Carles [ES/ES]; Calle Asturias 93, 2 ^o -2 ^o , E-08024 Barcelona (ES). PUJOL NOGUERA, Ferrán [ES/ES]; Avenida Francesc Maciá, 6, Sant Esteve de Sesrovires, E-08635 Barcelona (ES). FERNANDEZ, FORNER, Dolors [ES/ES]; Calle Roger de Flor 221, 5 ^o -4 ^o , E-08025 Barcelona (ES).		
(74) Agents: GOLDIN, Douglas, Michael et al.; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5LX (GB).		

(54) Title: 2-(3H)-OXAZOLONE DERIVATIVES AND THEIR USE AS COX-2 INHIBITORS

(57) Abstract

A 2-(3H)-oxazolone compound of formula (I) wherein R¹ is an alkyl $\text{r}-\text{NR}^4\text{R}^5$ group, wherein R⁴ and R⁵ each independently is hydrogen or an alkyl or benzyl group; R² is a naphthyl, tetrahydronaphthyl, unsubstituted phenyl or phenyl group, substituted by from 1 to 3 halogen atoms or alkyl, hydroxy, alkoxy or trifluoromethyl groups; and R³ is hydrogen or an alkyl group.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	R	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

tetrahydronaphthyl, unsubstituted phenyl or phenyl group substituted by from 1 to 3 halogen atoms (preferably chlorine or fluorine) or alkyl, hydroxy, alkoxy or trifluoromethyl groups; and

R^3 is hydrogen or an alkyl group.

The alkyl groups and moieties, such as in the alkoxy groups, mentioned in relation to the groups R^1 to R^5 are usually "lower" alkyl, that is containing up to 6 and particularly up to 4 carbon atoms, the hydrocarbon chain being branched or straight. A preferred alkyl group or moiety is methyl.

The substituents on the phenyl ring may be in any position. For example a single substituent may be on position 2, 3 or 4; or two substituents may be on positions 2 and 4 or 3 and 4.

Preferred compounds of formula (I) are those wherein R^1 is an alkyl or amino group, R^2 is a phenyl group substituted by one or two halogen atoms (especially chlorine or fluorine) and R^3 is hydrogen.

The substituents on the phenyl group represented by R^2 may be the same or different.

Of outstanding interest are:

3-(4-fluorophenyl)-4-(4-methylsulphonylphenyl)-2-(3H)-oxazolone, 3-(2-fluorophenyl)-4-(4-aminosulphonylphenyl)-2-(3H)-oxazolone, 3-(3,4-dichlorophenyl)-4-(4-aminosulphonylphenyl)-2-(3H)-oxazolone and 3-(2,4-difluorophenyl)-4-(4-aminosulphonylphenyl)-2-(3H)-oxazolone.

The present invention also provides processes for preparing a compound of formula (I) which depend on the definition of R^1 .

The present invention provides a process for the preparation of a compound of formula (I) wherein R^1 is an alkyl or $-NR^4R^5$ group in which R^4 and R^5 are other than hydrogen, viz. a 2-(3H)-oxazolone derivative of formula (II):


2-(3H)-OXAZOLONE DERIVATIVES AND THEIR USE AS COX-2 INHIBITORS

This invention relates to new therapeutically useful 2-(3H)-oxazolone derivatives, to processes for their preparation and to pharmaceutical compositions containing them.

The mechanism of action of non steroidial anti-inflammatory drugs is believed to be the inhibition of the enzyme cyclooxygenase (COX) and consecutively the conversion of the arachidonic acid into prostaglandines. The identification of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes led to the hypothesis that the inhibition, particularly selective inhibition, of COX-2 would reduce inflammation without the side effects of classical non steroidial anti-inflammatory drugs, gastric and renal toxicity.

In accordance with this hypothesis, we have now found that certain 2-(3H)-oxazolone derivatives inhibit COX-2 and selectively inhibit COX-2 in preference to COX-1. These derivatives have efficacy and good tolerance in the treatment of COX-2 mediated diseases, such as inflammation, pain, fever and asthma, and fewer side effects, such as ulcerogenic activity.


Accordingly the present invention provides a 2-(3H)-oxazolone compound of formula (I):




wherein:

R¹ is an alkyl or -NR⁴R⁵ group, wherein R⁴ and R⁵ each independently is hydrogen or an alkyl or benzyl group;

R² is a naphthyl (preferably 2-naphthyl),




wherein R^{1a} is an alkyl or -NR^{4a}R^{5a} group in which R^{4a} and R^{5a} each independently is an alkyl or benzyl group, and R² and R³ are as defined above which comprises reacting a carbamate of formula (V) :




wherein R^{1a}, R² and R³ are as defined above with anhydrous acetic acid.

The carbamate of formula (V) may be obtained, for example, by reacting a phenacyl alcohol of formula (III) :




wherein R^{1a} and R³ are as defined above, with an isocyanate of formula (IV) :



wherein R² is as defined above.

The reaction between the phenacyl alcohol of formula (III) and the isocyanate of formula (IV) may be carried out by heating a mixture of these two starting materials, optionally in the presence of an organic solvent such as toluen or xylene, at a temperature of from 80°C to 200°C.


The carbamate of formula (V) may also be prepared by reacting a thio derivative of formula (VI):




wherein R^{1a}, R² and R³ are as defined above, with an oxidizing agent, preferably magnesium monoperoxyphthalate or 3-chloroperoxybenzoic acid. The reaction is preferably carried out in an organic solvent such as a mixture of methylene chloride with methanol or ethanol, at a temperature of from 10°C to 40°C.

The carbamate of formula (V) may be isolated after each process by known methods. The carbamate may be heated to a temperature of from 80°C to 120°C with an excess of anhydrous acetic acid to give the compound of formula (II).

The present invention also provides a process for the preparation of a compound of formula (I) wherein R¹ is an alkyl group, viz. a 2-(3H)-oxazolone derivative of formula (VII):




wherein R^{1b} is an alkyl group and R^2 and R^3 are as defined above by reacting a mercapto derivative of formula (VIII):




wherein R^{1b}, R² and R³ are as defined above with an oxidizing agent, preferably with magnesium monoperoxyphthalate or 3-chloroperoxybenzoic acid.

The reaction between the mercapto derivative of formula (VIII) and the oxidizing agent is preferably carried out, as previously disclosed for the compound of formula (VI), in an organic solvent such as a mixture of methylene chloride with methanol or ethanol, at a temperature of from 10°C to 40°C.

The present invention additionally provides a process for the preparation of a compound of formula (I) wherein R¹ is a -NR⁴R⁵ group, viz. the 2-(3H)-oxazolone derivative of formula (IX):



wherein R², R³, R⁴ and R⁵ are as defined above by reacting a chlorosulphonyl derivative of formula (XI):



wherein R² and R³ are as defined above with an amine of formula (XII) :



wherein R⁴ and R⁵ are as defined above.


This reaction is preferably carried out at a temperature of from 10°C to 40°C.

The chlorosulphonyl derivative of formula (XI) may, for example, be prepared by reacting a compound of formula (X) :




wherein R² and R³ are as defined above with chlorosulphonic acid, preferably at a temperature of from 80°C to 120°C.

The present invention further provides a process for the preparation of a compound of formula (I) wherein R¹ is a -NR⁴R⁵ group wherein R⁴ and R⁵ are hydrogen, viz, the 2-(3H)-oxazolone derivative of formula (XIII) :



wherein R^2 and R^3 are as defined above by debenzylation of the corresponding compound of formula (IX) wherein R^4 and R^5 are as defined above with the proviso that at least one, preferably both, of R^4 and R^5 is a benzyl group, for example the 2-(3H)-oxazolone derivative of formula (XIV):



wherein R^2 and R^3 are as defined above.

The debenzylation is preferably carried out with an excess of trifluoroacetic, sulphuric or methanesulphonic acid at a temperature of from 0°C to 120°C.

The intermediates of formulae (III) and (VI) used in the preparation of the compounds of the invention may be prepared by methods disclosed in the literature, for example, in M.F. Saettone, J. Org. Chem. 31, p. 1959 (1966).

The intermediate compounds of formulae (VIII) and (X) may be prepared by the same process disclosed for the preparation of compounds of formula (II), with the appropriate starting materials.

The following biological tests and data further illustrate this invention.

For the whole-cell COX-1 and COX-2 assays, stock solutions (10^{-3}M) of the drugs were dissolved in 50%

dimethylsulphoxide, and further dilutions were done with medium. Drug vehicle, at concentrations employed, did not affect enzyme activities.

Inhibition of Cyclooxygenase-1 (COX-1) activity in human platelets

Platelets were isolated from peripheral human blood obtained from healthy donors who had denied taking any non-steroidal anti-inflammatory drugs during at least the previous week. The blood was anticoagulated with 2 mg/ml sodium EDTA and centrifuged at 180 g for 10 min. at room temperature to obtain platelet-rich plasma. The platelet-rich plasma was centrifuged at 2000 g for 20 min. at 4°C to obtain a platelet pellet. Cells were washed twice with PBS without Ca²⁺ and Mg²⁺ and resuspended to 5 x 10⁷ cells with Hank's balanced salt solution (HBSS). Platelets (10⁷) were preincubated with the drugs for 15 min. at 37°C and incubations were continued for a further 15 min. in the presence of 50 μM arachidonic acid. The production of thromboxane B₂ in response to arachidonic acid was measured in the supernatants using a solid-phase immunoassay (ELISA). The results are expressed as the mean of the IC₅₀ values obtained from three independent experiments.

Inhibition of Cyclooxygenase-2 (COX-2) activity in HUV-EC-C cell line

The human endothelial cell line HUV-EC-C expresses selectively cyclooxygenase-2 isoenzyme after treatment with phorbol 12-myristate 13-acetate (PMA) (Miralpeix et al., "Agents and Actions", 44: S274 (1995)). HUV-EC-C cells were grown on Ham's F12K medium containing 10% fetal bovine serum, 100 μg/ml heparin and 50 μg/ml Endothelial Cell Growth Supplement (ECGS). Experiments were performed with HUV-EC-C passage 19-27. Cells (2x10⁴) were seeded onto 96-well plates and made quiescent by removing the growth factor for 48 h before the initiation of the experiments. Quiescent HUV-EC-C cells were treated with 50 nM TPA for 6 h at 37°C to induce the COX-2 isoenzyme. The culture medium was then changed and cells were incubated with drugs for 30 min. at 37°C.

Arachidonic acid (50 μ M) was then added, and the cells were incubated for a further 30 min. The production of prostaglandine E₂ in response to arachidonic acid was measured in the supernatants using a solid-phase immunoassay (ELISA). The results are expressed as the mean of the IC₅₀ values obtained from three independent experiments.

Ulcerogenic activity

Animals: Male Wistar (Interfauna, U.K., Ltd.) weighing about 120-150g were used. They were maintained on a 12:12 hour light-dark cycle (lights on at 7:00 a.m.) at room temperature (22 \pm 1°C). The animals were fasted for 18h prior to the experiment with free access to drinking water.

Procedure: Experiments were performed from 9 to 17h. The compounds were administered by the oral route and the animals were sacrificed 6 hours after drugs dosage. The stomach of each rat was removed, opened and gently washed. The macroscopic severity of the erosions was assessed using a parametric scale (Cosen and Mazure), evaluating the number and size of the ulcers in the glandular stomach. Thus, each stomach was classified with an index lesion and compared with the gastrolesivity induced by ketorolac 100 mg/kg p.o., used as a positive standard. The treatments were randomized in each experiment.

Anti-inflammatory activity (adjuvant arthritis)

Male Wistar rats weighing 175-200g with free access to food and water were used. On day 0, the animals received an intraplantar injection of a suspension of Mycobacterium tuberculosis in paraffin oil (0.5 mg/rat) on the left hind paw. A group of 8 nonarthritic control rats were injected with paraffin oil alone. On days 11 and 14 after induction of arthritis, the volume of the hind paw of each rat was measured using a water plethysmograph. Animals whose paw volumes increased during that time were selected. Rats were distributed into groups of 8 having equal mean paw volumes and an approximately equal standard deviation.

Test compounds were administered p.o. once daily for 7 days (days 14-20). Nonarthritic and arthritic control rats

received vehicle alone for 7 days. The hind paw volumes were measured 20h after the last dose (on day 21). The body weight was determined every second day.

The results are expressed as the percentage of inhibition of inflammation (paw volume) for each treatment group, considering both the arthritic and nonarthritic vehicle controls. The ANOVA test was used for statistical studies.

Drugs

For the whole-cell COX-1 and COX-2 assays stock solutions (10^{-3} M) of the drugs were dissolved in 50% dimethylsulphoxide, and further dilutions were done with medium. The drug vehicle, at the concentrations employed, did not affect the enzyme activities.

For the in vivo assays all drugs were administered in vehicle (0.1% Tween 80 + 0.5% methylcellulose in distilled water) in a volume of 5 ml/kg.

Results

The results obtained from the biological assays are shown in Tables 1, 2 and 3.

TABLE 1
Inhibition of COX-1 and COX-2

COMPOUND (*)	COX-1 (μ M) (**)	COX-2 (μ M) (**)	Ratio COX-1:COX-2
Indomethacin	0.047	0.15	0.3
6	127	3.2	39.6
9	>100	0.11	>909
12	>100	0.4	>250
16	27.9	0.008	3487
17	>100	0.03	>3333
18	1.5	0.53	2.8
20	3.5	0.06	58.3
23	4.6	0.26	17.7
26	22.6	0.0096	2354
27	8.9	0.1	89

(*) See structures in Table 4. Indomethacin is 1-(4-chlorobenzoyl)-5-methoxy-2-m thyindol -3-acetic acid, a non steroidial anti-inflammatory drug.

(**) Results expressed as IC₅₀ values.

TABLE 2: Anti-inflammatory activity

COMPOUND	% Inhibition (dose, mg/kg)
Indomethacin	64 (1)
6	52 (3)
18	63 (1)
20	67 (1)
23	62 (1)
26	65 (1)
27	64 (1)

TABLE 3: Ulcerogenic activity

COMPOUND	UD ₅₀ (mg/kg)
Indomethacin	17
6	>100
20	>100
26	>100
27	>100

As shown in Table 1, the compounds of formula (I) are selective and potent COX-2 inhibitors. We have found that the compounds of the examples are more effective in inhibiting COX-2 activity than they are inhibiting COX-1 activity, whereas the reference compound indomethacin is a potent and selective COX-1 inhibitor. Due to their low COX-1 activity, the compounds of formula (I) present an important anti-inflammatory activity (see Table 2) and the benefit of significantly less harmful side effects than the non-steroidal anti-inflammatory drugs commonly used (e.g. gastrointestinal toxicity (see Table 3), renal side effects, reduced effect on bleeding times and asthma induction in

aspirin-sensitive subjects).

The present invention provides a compound of formula (I) for use in a method of treatment of the human or animal body by therapy, in particular for the treatment of pain, fever or inflammation, to inhibit prostanoid-induced smooth muscle contraction or for the prevention of colorectal cancer.

The present invention also provides the use of a compound of formula (I) in the manufacture of a medicament for the treatment of pain, fever or inflammation, to inhibit prostanoid-induced smooth muscle contraction or for the prevention of colorectal cancer.

The compounds of formula (I) are useful for relief of pain, fever and inflammation of a variety of conditions including rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, dysmenorrhoea, headache, toothache, sprains and strains, myositis, neuralgia, synovitis, bursitis, tendinitis, injuries, following surgical and dental procedures and arthritis including rheumatoid arthritis, osteoarthritis, gouty arthritis, spondyloarthropathies, systemic lupus erythematosus and juvenile arthritis. They may also be used in the treatment of skin inflammation disorders such as psoriasis, eczema, burning and dermatitis. In addition, such compounds may be used for the prevention of colorectal cancer.

The compounds of formula (I) will also inhibit prostanoid-induced smooth muscle contraction and therefore may be used in the treatment of dysmenorrhoea, premature labour, asthma and bronchitis.

The compounds of formula (I) can be used as alternative to conventional non-steroidal anti-inflammatory drugs, particularly where such non-steroidal anti-inflammatory drugs may be contra-indicated such as the treatment of patients with gastrointestinal disorders including peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis, Crohn's disease, inflammatory bowel syndrome and irritable bowel syndrome, gastrointestinal bleeding and coagulation disorders, kidney

disease (e.g. impaired renal function), those prior to surgery or taking anticoagulants, and those susceptible to non steroidal anti-inflammatory drugs induced asthma.

The compounds can further be used to treat inflammation in diseases such as vascular diseases, migraine headaches, periarteritis nodosa, thyroiditis, aplastic anaemia, Hodgkin's disease, scleroderma, type I diabetes, myasthenia gravis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, hypersensitivity, conjunctivitis, gingivitis and myocardial ischaemia.

Compounds of the present invention are inhibitors of cyclooxygenase-2 enzyme and are thereby useful to treat the cyclooxygenase-2 mediated diseases enumerated above.

The present invention furthermore provides a pharmaceutical composition which comprises, as active ingredient, at least one 2-(3H)-oxazolone derivative of formula (I) and a pharmaceutically acceptable carrier or diluent. Preferably the compositions are in a form suitable for oral, topical, inhalation, rectal, transdermal, nasal or parenteral administration. The pharmaceutically-acceptable carriers or diluents which are admixed with the active compound or compounds to form the compositions of this invention are well known *per se* and the actual excipients used depend *inter alia* on the intended method of administration of the compositions. Compositions of this invention are preferably adapted for administration *per os*.

In this case, the compositions for oral administration may take the form of tablets, capsules, lozenges or effervescent granules or liquid preparations such as elixirs, syrups or suspensions, all containing one or more compounds of the invention. Such preparations may be made by methods well known in the art, for instance by mixing the 2-(3H)-oxazolone derivative of formula (I) with the pharmaceutically acceptable carrier or diluent.

The diluents which may be used in the preparation of the compositions include those liquid and solid diluents which are compatible with the active ingredient, together with colouring or flavouring agents if desired. Tablets or capsules may conveniently contain between 10 and 500 mg and

preferably from 15 to 100 mg of active ingredient. The compounds may also be incorporated into pellets coated with appropriate natural or synthetic polymers known in the art to produce sustained release characteristics or incorporated with polymers into tablet form to produce the same characteristics.

The liquid compositions adapted for oral use may be in the form of solutions, suspensions or aerosols. The solutions may be aqueous-alcoholic solutions of a 2-(3H)-oxazolone in association with, for example, sucrose or sorbitol to form a syrup. The suspensions may comprise an insoluble or microencapsulated form of an active compound of the invention in association with water and other acceptable solvents together with a suspending agent or flavouring agent.

Compositions for inhalation administration may be in the form of solutions, suspensions or micronized powder, contained in an appropriate inhaler.

Compositions for parenteral injection may be prepared in the form of microemulsions or microsuspensions in water or an appropriate parenteral injection fluid.

In human therapy, the doses of the 2-(3H)-oxazolone derivatives depend on the desired effect and duration of the treatment; adult doses are generally between 15 mg and 500 mg per day. In general the physician will decide the posology taking into account the age and weight of the patient being treated.

The 2-(3H)-oxazolone derivatives of formula (I) may be used in a method of treatment of any of the above conditions which comprises administering to a subject in need of such treatment an effective amount of the derivative of formula (I).

The following Examples further illustrate the invention.

EXAMPLE 1

a) A mixture of 4-methylsulphonylphenacyl alcohol (3 g; 0.014 moles) m.p. 133-135°C, and 4-fluorophenyl isocyanate (5 ml; 0.044 moles) was stirred for 1 hour at

100°C. After cooling, the resulting solid was treated with diisopropyl ether (30 ml), collected by filtration and washed with a 10% mixture of methanol in diethyl ether. 4-methylsulphonylphenacyl N-(4-fluorophenyl) carbamate (3.5 g) was obtained as a white solid, m.p. 198-200°C (d).

b) A solution of the above compound (3 g; 0.0085 moles) in anhydrous acetic acid (30 ml) was boiled under reflux for 8 hours. The solvent was removed in vacuo the residue crystallized from a mixture of acetonitrile (10 ml) and diisopropyl ether (20 ml) and then recrystallized from a mixture of ethanol and methylene chloride. 3-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-(3H)-oxazolone (1.9 g), was obtained, m.p. 170-172°C. This compound has another crystalline form with m.p. 152-153°C.

EXAMPLE 2

a) A solution of 4-methylthiophenacyl alcohol (1 g; 5.5 mmoles) and 4-bromophenyl isocyanate (1.08 g; 5.4 mmoles) in anhydrous xylene (10 ml) was boiled under reflux for 5 hours. Then the reaction mixture was cooled and the solid was filtered off and washed with diisopropyl ether to give 4-methylthiophenacyl N-(4-bromophenyl) carbamate as a white solid (1.8 g).

b) A solution of the above carbamate (1.8 g; 4.7 mmoles) in anhydrous acetic acid (18 ml) was boiled under reflux for 16 hours, the solvent removed in vacuo and the residue treated with acetone. The resulting white solid was filtered off and 3-(4-bromophenyl)-4-(4-methylthiophenyl)-2-(3H)-oxazolone (1 g) was obtained.

c) To a solution of the above compound (1 g; 2.7 mmoles) in methanol (3 ml) and methylene chloride (17 ml), magnesium monoperoxyphthalate hexahydrate (2.13 g; 4.3 mmoles) was slowly added, and the mixture stirred at room temperature for 2 hours. Then it was washed with 4M sodium bicarbonate aqueous solution, dried (Na_2SO_4) and the solvent removed under reduced pressure. The residue was recrystallized from methylene chloride-ethanol to give 3-(4-bromophenyl)-4-(4-methylsulfonylphenyl)-2-(3H)-oxazolone (0.63 g), m.p. 217-219°C.

EXAMPLE 3

a) A solution of phenacyl N-(4-fluorophenyl) carbamate (9.6 g; 35 mmoles) in anhydrous acetic acid (96 ml) was boiled under r flux for 16 hours. Th solvent was removed under reduced pressure and a solid crystallized, which was collected by filtration and washed with diethyl ether. 3-(4-fluorophenyl)-4-phenyl-2-(3H)-oxazolone (7.8 g) was obtained, m.p. 145-147°C.

b) A mixture of the above compound (4 g; 15.7 mmoles) and chlorosulphonic acid (2.1 ml; 31.6 mmoles) was heated at 100°C for 4 hours, cooled and then poured into iced-water. The precipitated solid was extracted with ethyl acetate, dried (Na₂SO₄) and the solvent removed in vacuo. To the residue, concentrated ammonium hydroxide (40 ml) was added, stirred at room temperature for half an hour and extracted with methylene chloride. The organic solution was dried (Na₂SO₄) the solvent removed under reduced pressure and the residue recrystallized from ethanol. 3-(4-fluorophenyl)-4-(4-aminosulfonylphenyl)-2-(3H)-oxazolone (0.89 g) was obtained, m.p. 211-213°C.

EXAMPLE 4

a) A solution of 4-(N,N-dibenzylaminosulfonyl)phenacyl N-(3,4-dichlorophenyl) carbamate (2.6 g; 4.46 mmoles) in anhydrous acetic acid (25 ml) was boiled under reflux for 6 hours. The solvent was removed under reduced pressure and the obtained oil was treated with diethyl ether. 3-(3,4-dichlorophenyl)-4-[4-(N,N dibenzylaminosulfonyl)phenyl]-2-(3H)-oxazolone crystallized (2.0 g), m.p. 128-130°C.


b) A solution of the above compound (2 g; 3.54 mmoles) in methanesulfonic acid (15 ml) was stirred at 100°C for half an hour. The reaction mixture was poured into iced-water, the precipitated solid collected by filtration, and then treated with ethanol. The insoluble solid was filtered off and the solution was passed through a chromatography column containing silica gel and methylene chloride-methanol 95:5 as eluent.

3-(3,4-dichlorophenyl)-4-(4-aminosulfonylphenyl)-2-(3H)-

oxazolon (0.9 g) was obtained, m.p. 158-161°C.

Other 2-(3H)-oxazolone derivatives of formula (I) in Table 4 were prepared according to the process s disclos d in these Examples, but with th appropriate starting materials.

TABLE 4



Compound	R ¹	R ²	R ³	Method Example	m.p. °C
1	H ₃ C	C ₆ H ₅	H	1	207-210
2	"	4H ₃ C-C ₆ H ₄	"	"	213-214
3	"	3H ₃ C-C ₆ H ₄	"	"	195-197
4	"	2F-C ₆ H ₄	"	"	186-187
5	"	3F-C ₆ H ₄	"	2	138-139
6	"	4F-C ₆ H ₄	"	1,2	170-172
7	"	3Cl-C ₆ H ₄	"	1	177-178
8	"	4Cl-C ₆ H ₄	"	1	220-221
9	"	4Br-C ₆ H ₄	"	2	217-219
10	"	4F,C-C ₆ H ₄	"	1	189-190
11	"	3Cl,4H,CO-C ₆ H ₃	"	1	154-156
12	"	2,4diF-C ₆ H ₃	"	1	155-156
13	"	3,4diF-C ₆ H ₃	"	1	177-178
14	"	3Cl,4F-C ₆ H ₃	"	1	175-177
15	"	2,4diCl-C ₆ H ₃	"	1	199-200
16	"	3,4diCl-C ₆ H ₃	"	1	197-199
17	"	2-naphthyl	"	1	222-223
18	H ₂ N	4F-C ₆ H ₄	"	3	211-213
19	"	3Cl,4F-C ₆ H ₃	"	4	247-249
20	"	3,4diCl-C ₆ H ₃	"	4	158-161

21	(C ₆ H ₅ -CH ₂) ₂ N	3Cl, 4F-C ₆ H ₃	"	1	128-130
22	H ₃ C	4F-C ₆ H ₄	H ₃ C	1	205-206
23	H ₂ N	4Cl-C ₆ H ₄	H	4	211-212
24	"	4Cl, 3F-C ₆ H ₃	"	"	186-187
25	"	3Cl-C ₆ H ₄	"	"	176-177
26	"	2F-C ₆ H ₄	"	"	178-179
27	"	2,4diF-C ₆ H ₃	"	"	190-192
28	H ₃ C-NH	"	"	"	136-138
29	C ₆ H ₅ -CH ₂ -N-CH ₃	"	"	1	125-127
30	(H ₃ C) ₂ N	"	"	"	157-159

The following Examples illustrate pharmaceutical compositions according to the present invention and procedures for their preparation.

EXAMPLE 5

10,000 Tablets each containing 50 mg of 3-(4-chlorophenyl-4-(4-methylsulfonyl-phenyl)-2-(3H)-oxazolone (active ingredient) were prepared from the following formulation:

Active ingredient	500 g
Microcrystalline cellulose	390 g
Spray dried Lactose	1.990 g
Carboxymethyl starch	80 g
Sodium stearyl fumarate	20 g
Colloidal silicon dioxide	20 g

Procedure

All the powders were passed through a screen with an aperture of 0.6 mm, then mixed in a suitable mixer for 20 minutes and compressed into 300 mg tablets using 9 mm discs and flat bevelled punches. The disintegration time of the tablets was about 3 minutes.

EXAMPLE 6

100,000 capsules each containing 100 mg of 3-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-(3H)-oxazolone (active ingredient) were prepared from the following formulation:


Active ingredient	10 kg
Lactose monohydrate	20 kg
Corn starch	2 kg
Magnesium stearate	0.4 kg
Colloidal silicon dioxide	0.2 kg

Procedure

The above ingredients were sieved through a 60-mesh sieve, and were loaded into a suitable mixer and filled into 100,000 gelatine capsules.

CLAIMS

1. A 2-(3H)-oxazolone compound of formula (I):



wherein:

R^1 is an alkyl or $-NR^4R^5$ group, wherein R^4 and R^5 each independently is hydrogen or an alkyl or benzyl group;

R^2 is a naphthyl, tetrahydronaphthyl, unsubstituted phenyl or phenyl group substituted by from 1 to 3 halogen atoms or alkyl, hydroxy, alkoxy or trifluoromethyl groups; and

R^3 is hydrogen or an alkyl group.

2. A compound according to claim 1 in which R^2 is a 2-naphthyl group or a phenyl group substituted by 1 or 2 halogen atoms.

3. A compound according to claim 1 or 2 wherein R^2 is a phenyl group substituted by from 1 to 3 chlorine or fluorine atoms.

4. A compound according to any one of the preceding claims in which the alkyl groups or moieties contain from 1 to 6 carbon atoms.

5. 3-(4-fluorophenyl)-4-(4-methylsulphonylphenyl)-2-(3H)-oxazolone;

3-(2-fluorophenyl)-4-(4-aminosulphonylphenyl)-2-(3H)-oxazolone;


3-(3,4-dichlorophenyl)-4-(4-aminosulphonylphenyl)-2-(3H)-oxazolone; and

3-(2,4-difluorophenyl)-4-(4-aminosulphonylphenyl)-2-(3H)-oxazolone.

6. A process for the preparation of a compound of


formula (I) as defined in any one of the preceding claims which comprises:

a) when R^1 is an alkyl or $-NR^4R^5$ group in which R^4 and R^5 are other than hydrogen, reacting a carbamate of formula (V) :




wherein R^2 and R^3 are as defined in claim 1 and R^{1a} is an alkyl or $-NR^{4a}R^{5a}$ group wherein R^{4a} and R^{5a} each independently is an alkyl or benzyl group with anhydrous acetic acid;

b) when R^1 is an alkyl group, reacting a mercapto derivative of formula (VIII) :



wherein R^2 and R^3 are as defined in claim 1 and R^{1b} is an alkyl group with an oxidizing agent;

c) when R^1 is a $-NR^4R^5$ group wherein R^4 and R^5 are as defined in claim 1, reacting a chlorosulphonyl derivative of formula (XI) :




wherein R² and R³ are as defined in claim 1 with an amin of formula (XII) :



(XII)

wherein R⁴ and R⁵ are as defined above; or

d) when R¹ is a -NR⁴R⁵ group wherein R⁴ and R⁵ are hydrogen, debenzylating the corresponding compound of formula (IX) :



wherein R², R³, R⁴ and R⁵ are as defined in claim 1 with the proviso that at least one of R⁴ and R⁵ is a benzyl group.

7. A pharmaceutical composition which comprises, as active ingredient, at least one compound of formula (I) as defined in any one of claims 1 to 5 and a pharmaceutically acceptable carrier or diluent.

8. A compound of formula (I) as defined in any one of claims 1 to 5 for use in a method of treatment of the human or animal body by therapy.

9. A compound of formula (I) as defined in any one of claims 1 to 5 for use in the treatment of pain, fever or inflammation, to inhibit prostanoid-induced smooth muscle contraction or for the prevention of colorectal cancer.

10. Use of a compound of formula (I) as defined in any one of claims 1 to 5 in the manufacture of medicament for the treatment of pain, fever or inflammation, to inhibit prostanoid-induced smooth muscle contraction or for the prevention of colorectal cancer.

INTERNATIONAL SEARCH REPORT

Inte: n Application No
PCT/EP 97/01386

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D263/38 A61K31/42

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 27980 A (G.D.SEARLE & CO) 8 December 1994 see claims -----	1-10

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *'A' document defining the general state of the art which is not considered to be of particular relevance
- *'E' earlier document but published on or after the international filing date
- *'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *'O' document referring to an oral disclosure, use, exhibition or other means
- *'P' document published prior to the international filing date but later than the priority date claimed

- *'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *'A' document member of the same patent family

2

Date of the actual completion of the international search

12 June 1997

Date of mailing of the international search report

20.06.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentstaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Henry, J

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/01386

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9427980 A	08-12-94	US 5380738 A AU 6949594 A EP 0699192 A JP 8510736 T	10-01-95 20-12-94 06-03-96 12-11-96